Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study
J Eur Acad Dermatol Venereol
.
2021 Aug;35(8):e485-e487.
doi: 10.1111/jdv.17279.
Epub 2021 May 1.
Authors
J R Georgakopoulos
1
,
A Mufti
1
,
R Vender
2
3
,
V H Prajapati
4
5
6
7
8
9
,
J Yeung
1
10
11
12
Affiliations
1
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
2
Department of Dermatology, McMaster University, Hamilton, ON, Canada.
3
Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada.
4
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
5
Division of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
6
Division of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
7
Dermatology Research Institute, Calgary, AB, Canada.
8
Skin Health & Wellness Centre, Calgary, AB, Canada.
9
Probity Medical Research Inc, Calgary, AB, Canada.
10
Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
11
Women's College Hospital, Toronto, ON, Canada.
12
Probity Medical Research Inc, Waterloo, ON, Canada.
PMID:
33872431
PMCID:
PMC8250560
DOI:
10.1111/jdv.17279
No abstract available
Publication types
Letter
Multicenter Study
MeSH terms
Biological Products*
Biological Therapy
COVID-19*
Humans
Incidence
Prognosis
Psoriasis* / drug therapy
Psoriasis* / epidemiology
Retrospective Studies
SARS-CoV-2
Substances
Biological Products